Skip to main content

Table 3 Correlation of EGFR mutations with clinicopathological features of NSCLC patients

From: The mutation rates of EGFR in non-small cell lung cancer and KRAS in colorectal cancer of Chinese patients as detected by pyrosequencing using a novel dispensation order

Variable Number (%) EGFR Univariate Multivariate
Mutation (%) Wild type (%) Odds ratio (95 % CI) p value Odds ratio (95 % CI) p value
Gender
Male 334 (67.61) 108 (32.34) 226 (67.66) Ref.   Ref.  
Female 160 (32.39) 68 (42.50) 92 (57.50) 1.55 (1.05–2.28) 0.028 0.64 (0.32–1.28) 0.209
Age
≤65 271 (54.86) 122 (45.02) 149 (54.98) 2.56 (1.73–3.78) <0.001 2.51 (1.65–3.81) <0.001
>65 223 (45.14) 54 (24.22) 169 (75.78) Ref.   Ref.  
Smoking history
Ever smoker 348 (70.45) 102 (29.31) 246 (70.69) Ref.   Ref.  
Never smoker 146 (29.55) 74 (50.68) 72 (49.32) 2.48 (1.66–3.69) <0.001 3.63 (1.83–7.19) <0.001
Never smoker
Male 21 (14.38) 11 (52.38) 10 (47.62) Ref.    
Female 125 (85.62) 63 (50.40) 62 (49.60) 0.92 (0.37–2.33) 0.867   
Pathologic stage
I + II 171 (34.62) 55 (32.16) 116 (67.84) Ref.   Ref.  
III + IV 323 (65.38) 121 (37.46) 202 (62.54) 1.26 (0.85–1.87) 0.243 1.45 (0.94– 2.24) 0.089
Pathology
Non-ADC 184 (32.75) 35 (19.02) 149 (80.98) Ref.   Ref.  
ADC 310 (62.75) 141 (45.48) 169 (54.52) 3.55 (2.31–5.46) <0.001 3.57 (2.28–5.61) <0.001
Male 212 (68.39) 86 (40.57) 126 (59.43) Ref.    
Female 98 (31.61) 55 (56.12) 43 (43.88) 1.87 (1.15–3.04) 0.011   
Never smoker ADC
Male 15 (16.13) 9 (60.00) 6 (40.00) Ref.    
Female 78 (83.87) 51(65.38) 27(34.62) 1.26 (0.41–3.91) 0.69   
Differentiation
Well 145 (29.35) 50 (34.48) 95 (65.52) Ref.   Ref.  
Moderate 249 (50.40) 92 (36.95) 157 (63.05) 1.11 (0.73–1.71) 0.623 1.14 (0.72–1.82) 0.573
Poor 97 (19.64) 34 (35.05) 63 (64.95) 1.03 (0.60–1.76) 0.927 1.10 (0.60–2.00) 0.759
  1. EGFR epidermal growth factor receptor, NSCLC non-small cell lung cancer, ADC adenocarcinoma, CI confidence interval, Ref. reference group